Mediana "1Q Sales 14.2 Billion KRW... Maintains Profitability Trend"

[Asia Economy Reporter Hyunseok Yoo] Mediana announced on the 26th that its consolidated sales for the first quarter reached 14,157.05 million KRW, a 3.5% increase compared to the same period last year. Operating profit and net profit were 2,171.39 million KRW and 2,512.57 million KRW, respectively. The company explained that the 31.9% decrease in operating profit compared to the same period last year was mainly due to a 6.7% decline in the exchange rate.

The company attributed the performance increase to sales generated from medical devices that obtained overseas certifications last year. A company representative stated, “New products such as the V20, which received FDA approval in the U.S. last year, and the ‘M2000’ biosignal monitor, a new product for Medtronic that additionally obtained certification from the Japanese Ministry of Health, Labour and Welfare, started generating sales from the first quarter. Demand for automated external defibrillators and professional defibrillators has also increased, raising brand awareness domestically and internationally, so continuous sales growth is expected in the future.”

In particular, the V20 features state-of-the-art IoT integration, allowing wireless transmission to the hospital’s EMR system without the nurse having to manually record the patient’s condition multiple times. This significantly reduces the workload of medical staff and includes a patient condition prediction system, enabling earlier prognosis determination. This product is already installed and operating in large quantities at major university hospitals in Korea.

Mediana is also focusing on expanding its business area by developing consumables such as catheters in addition to advanced medical devices. A company representative explained, “We are developing products including PICC (Peripherally Inserted Central Catheter) and a 3D navigation endoscopic catheter, which is a national project under the Ministry of Science and ICT. We will expand the profit structure to diversify sales.”

Gil Munjong, Chairman of Mediana, said, “This year, based on stable business operations, active research will continue, including national project execution and new product development with partners. To maintain the upward trend in performance, we will accelerate certification of new products in each country and consistently strive to expand market share through strengthening sales capabilities.”